Dimerix Limited (SBMJF)

Market Cap	201.44M
Revenue (ttm)	456.63K
Net Income (ttm)	-14.43M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214
Average Volume	4,416
Open	0.3500
Previous Close	n/a
Day's Range	0.3500 - 0.3500
52-Week Range	0.2500 - 0.3500
Beta	0.53
RSI	n/a
Earnings Date	Aug 28, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBMJF

Financial Performance

In 2024, Dimerix's revenue was 583,478, an increase of 1486.10% compared to the previous year's 36,787. Losses were -17.08 million, 23.7% more than in 2023.

Financial numbers in AUD